Friedreich's Ataxia News and Research

RSS
Friedreich's ataxia is an inherited disease that causes progressive damage to the nervous system resulting in symptoms ranging from gait disturbance and speech problems to heart disease. A well-known celebrity afflicted with Friedreich's ataxia is former major leaguer and noted historian Clinton Stewart.
Scripps Research receives CIRM grant for new research in stem cell biology and disease origins

Scripps Research receives CIRM grant for new research in stem cell biology and disease origins

Repligen anticipates 30% increase in total revenues for 2011

Repligen anticipates 30% increase in total revenues for 2011

USPTO grants new patent to Intellect's Alzheimer's vaccine

USPTO grants new patent to Intellect's Alzheimer's vaccine

Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen third quarter total revenue increases 26% to $7,068,000

Scientists develop Australia's first pluripotent stem cell lines using skin biopsies for FA disease

Scientists develop Australia's first pluripotent stem cell lines using skin biopsies for FA disease

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

New findings could help scientists devise optimal therapies for Friedreich's ataxia

New findings could help scientists devise optimal therapies for Friedreich's ataxia

Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

Muscular Dystrophy Association awards $14.1M in new grants

Muscular Dystrophy Association awards $14.1M in new grants

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

Penwest Pharmaceuticals signs merger agreement with Endo Pharmaceuticals

Penwest Pharmaceuticals signs merger agreement with Endo Pharmaceuticals

Endo to acquire Penwest for $5.00 per share

Endo to acquire Penwest for $5.00 per share

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Scientists identify IRP proteins to ensure iron balance for cell survival

Scientists identify IRP proteins to ensure iron balance for cell survival

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Tufts University's School of Arts and Sciences receives $9.5M grant to create research space

Tufts University's School of Arts and Sciences receives $9.5M grant to create research space